-
Targeted substances
- Triglyceride
- Bilirubin
- Carbamazepine
- Digoxin
- Methotrexate
- Bile acid
- Paraquat
- Myoglobin
- Cholesterol
- Inflammatory Mediators and Cytokines
- Leptin
- Ammonia
- Protein-bound toxins
- β2-MG
- Organophosphate
- PTH
- Rivaroxaban
- 2,4-dinitrophenol
- Ticagrelor
- Paracetamol
- Metformin
- ANA and ds-DNA titers
- Abrin
- Sodium valproate
- Amlodipine
- Estazolam
- Quetiapine
- Olanzapine
- Ziprasidone
- Vancomycin
- Organophosphorus
- Circulating Bacteria
- Liver Enzymes(e.g. ALT,AST)
- Vancomycin
- Gentamicin
- Poison
- Protein binded substance
- Antimicrobials
- Others
-
Benefits
- Improve QOL
- Decrease Vasopressor Needs
- Stabilize Hemodynamics
- Improve oxygenation
- Bridge to Liver Transplantation
- Reduce the incidence of adverse effect
- Shorten ICU stay
- Reduce bleeding complications
- Reduce Mechanical Ventilation
- Improve Respiratory Function
- Lower the mortality rate
- Improve Liver Function
- Improve sleep efficiency
- Improve HE
- Improve renal function
- Relieve Uremic Pruritis
- Reduce Cardiovascular Related Events
- Improve Survival Rate
- Remove inflammatory markers/ cytokines
- Reduce circulating bacterial load
- Improve disease symptoms
- Improve laboratory parameters
- Others
- Disease
- Endocarditis
- Poisoning/Drug overdose
- Leptospirosis
- Sepsis/ Septic Shock
- Multiple Myeloma
- Severe Acute Pancreatitis(SAP)
- Multiple Organ Dysfunction Syndrome(MODS)
- Rhabdomyolysis
- Dengue
- Leukemia-Sepsis
- Burn
- Trauma
- Open Heart Surgery
- Acute Respiratory Distress Syndrome (ARDS)
- Hepatic Encephalopathy(HE)
- End Stage Renal Disease(ESRD)
- Acute Kidney Injury(AKI)
- Systemic Lupus Erythematosus (SLE)
- Liver Transplantation
- Liver Failure(LF)
- Jaudice
- Subarachnoid Hemorrhage
- Symmetrical Peripheral Gangrene(SPG)
- Wasp Stings
- Acute Renal Failure
- Hepatitis
- Cardiopulmonary Bypass(CPB)
- Severe Liver Injury
- Henoch-Schönlein purpura (HSP)
- COVID-19
- Polymyositis
- Liver Cirrhosis
- Hyperbilirubinemia
- Maintenance Hemodialysis (MHD)
- Crush syndrome
- Human Immunodeficiency Virus(HIV)
- Immunological diseases (IMD)
- Hyperlipidemia
- Infection
- Others
-
The impact of hemoadsorption on antimicrobials
Furukawa T, Lankadeva Y, Bellomo R. [J]. Journal of Translational Critical Care Medicine, 2024, 6(3): e24-00011.
-
Effect of Different Blood Purification Methods on Residual Renal Function in Maintenance Hemodialysis Patients
Zhang G. [J]. Urology Research, 2024, 2(3): 1-6.
-
Successful Treatment of Cannabis and Methadone Overdose with Hemoperfusion - A Case Report
Ramteke V, Shingare [J] Indian J Nephrol. doi: 10.25259/IJN_436_2024
-
Add-on hemoperfusion in SARS-CoV-2-infected pregnant patients: a case series
Chiewroongroj S, Naorungroj T, Ratanarat R. [J]. Journal of Medical Case Reports, 2024, 18(1): 418.
-
Efficacy of the Cytokine Adsorption Therapy in Patients with Severe COVID-19-Associated Pneumonia: Lesson Learned from a Prospective Observational Study
Kusirisin P, Noppakun K, Trongtrakul K, et al. [J]. Blood Purification, 2024, 53(1): 10-22.
-
Rare skin color changes in an acute pancreatitis patient undergoing maintenance hemodialysis
Wang Z, Zhang L, Chen J. [J]. BMC nephrology, 2024, 25(1): 287.
-
Case Report: HA during Norwood Neonate Surgery with CPB
Xavier Bechtold, Amir-Reza Hosseinpour, et al. International Hemoadsorption Summit. 2023.
-
Cardiorenal Syndrome and Inflammation: A Forgotten Frontier Resolved by Sorbents?
Ramírez-Guerrero G, Ronco C, Reis T. [J]. Cardiorenal Medicine, 2024, 14(1): 454-458.
-
The role of blood purification therapies in the treatment of chronic kidney disease-associated pruritus: a systematic review
Marcello M, Marturano D, Ronco C, et al. [J]. Clinical Kidney Journal, 2024: sfae266.
-
CVVHDF combined with cytokine adsorption column ameliorates severe catheter-related bloodstream infection in a hemodialysis patient
Shen Y. [J]. SAGE Open Medical Case Reports, 2024, 12: 2050313X241272670.
-
Efficacy of HA380 hemoperfusion in the treatment of septic shock
Chen L, Zhou S, Wang C, et al. [J]. Journal of Translational Critical Care Medicine, 2024, 6(3): e24-00008.
-
A Study of Paraquat Poisoning Presentation, Severity, Management and Outcome in a Tertiary Care Hospital: Is There a Silver Lining in the Dark Clouds?
Goyal P, Gautam P L, Sharma S, et al. [J]. Indian Journal of Critical Care Medicine, 2024, 28(8): 742.
-
The Role of Early Hemoadsorption in Severe COVID-19 Treatment: a Pilot Randomized Controlled Trial
Surasit K, Srisawat N. [J]. Blood purification, 2024: 1-11.
-
Comparative efficacy of double plasma molecular adsorption system combined with plasma exchange versus plasma exchange in treating acute-on-chronic liver failure due to hepatitis B: A meta-analysis
Zhang L, Ma Y, Wang X, et al. [J]. Journal of Clinical Apheresis, 2024, 39(4): e22140.
-
High adsorption capacity of hemoperfusion on imipenem in critically ill patients with septic shock: a case report
Wang C, Li C, Yang P, et al. [J]. BMC Infectious Diseases, 2024, 24(1): 894.
-
Cost-effectiveness Analysis of HA Resin Hemoperfusion Combined with Hemodialysis in the Treatment of End-stage Renal Disease
Zhao Xinrui, Wang Dan, Liu Chunping, et al. [J].Health economic research, 2023, 40(8):40-44.
-
Effects of haemodialysis coupled with hemadsorption on uremic toxins removal, oxidative stress and cellular death
Marcello M, Virzi G M, Cantaluppi V, et al.[J]. Nephrology Dialysis Transplantation, 2024, 39(Supplement_1): gfae069-1528-1573.
-
Efficacy of Divinylbenzenic Resin in Removing Indoxyl Sulfate and P-cresol Sulfate in Hemodialysis Patients: Results from an In Vitro Study and an In Vivo Pilot Trial (xuanro4-Nature 3.2)
Rocchetti M T, Cosola C, di Bari I, et al. [J]. Toxins, 2020, 12(3): 170.
-
Classification of Uremic Toxins and Their Role in Kidney Failure
Rosner M H, Reis T, Husain-Syed F, et al. [J]. Clinical Journal of the American Society of Nephrology, 2021, 16(12): 1918-1928.
-
Plasma Aβ42:Aβ40 ratio as a biomarker for cognitive impairment in haemodialysis patients: a multicentre study
Chen X, Wang M, Niu J, et al. [J]. Clinical Kidney Journal, 2023, 16(11): 2129-2140.